# Ibandronate or Zoledronate in Treating Patients With Newly Diagnosed Bone Metastases From Breast Cancer

> **NCT00326820** · PHASE3 · UNKNOWN · sponsor: **Wales Cancer Trials Unit** · enrollment: 1404 (actual)

## Conditions studied

- Breast Cancer
- Hypercalcemia of Malignancy
- Metastatic Cancer

## Interventions

- **DRUG:** ibandronate sodium
- **DRUG:** zoledronic acid
- **DRUG:** Zolendronic Acid

## Key facts

- **NCT ID:** NCT00326820
- **Lead sponsor:** Wales Cancer Trials Unit
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2006-01
- **Primary completion:** 2012-12
- **Final completion:** 2015-10
- **Target enrollment:** 1404 (ACTUAL)
- **Last updated:** 2013-03-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00326820

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00326820, "Ibandronate or Zoledronate in Treating Patients With Newly Diagnosed Bone Metastases From Breast Cancer". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT00326820. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*